BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Ralph Mueller  ¹     Christoph Schlag  ²     Christoph Schmöcker  ³     Roland Greinwald  ¹     Luc Biedermann  ⁴     Michael Vieth  ⁵     Alfredo J. Lucendo  ⁶     Cecilio Santander  ⁷     Alex Straumann     Petr Hruz     Ahmed Madisch     Stephan Miehlke     Stephen E. Attwood     Arjan Bredenoord     Stefan Schubert     Constanza Ciriza De Los Ríos     Alain M. Schoepfer     Jamal Hayat     Ulri    
¹ Dr. Falk Pharma GmbH,Freiburg,Germany
² Klinikum rechts der Isar - TU München,München,Germany
³ Sana Klinikum Lichtenberg,Berlin,Germany
⁴ University Hospital Zurich,Zurich,Switzerland
⁵ Klinikum Bayreuth,Bayreuth,Germany
⁶ Hospital General de Tomelloso,Tomelloso,Spain
⁷ Hospital Universitario de la

Session
Novel insights in a new disease: Eosinophilic oesophagitis

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)